SCHEMBL4283502

SCHEMBL4283502

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)c([N+](=O)[O-])c2)c2c1CN(S(=O)(=O)c1cccc(F)c1)C2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
GAA P10253 4/20 0.46
ALDH1A1 P00352 4/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
MAPK1 P28482 1/20 0.43
WDR5 P61964 3/20 0.43
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
NOD1 Q9Y239 1/20 0.41
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279221 0.90 IGF1R (0.42) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4287268 0.89 TAAR1 (0.42) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4279263 0.86 IGF1R (0.39) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL1891290 0.83 IGF1R (0.45) MAPTGAALMNAL3MBTL1HTT
SCHEMBL14421913 0.82 MAPT (0.49) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4285001 0.82 IGF1R (0.57) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4281921 0.81 IGF1R (0.51) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4278011 0.81 MAPT (0.47) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4282875 0.80 IGF1R (0.45) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL4279306 0.80 MAPT (0.50) MAPTGAAALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 MAPT 2911/4885GAA 3673/4885ALDH1A1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.